drugset / Trial / NCT00670267
Oral Nadolol for the Treatment of Adults With Mild Asthma
Phase 1/2
Completed
10 enrolled
Invion, Inc.
Baylor College of Medicine · collabSandler Program for Asthma Research · collabUniversity of Houston · collab
NaSingle-groupOpen-labelTreatment
Summary
The purpose of this study is to confirm previous observations in asthmatics that chronic nadolol treatment reduces asthmatic airway hyper-responsiveness.
Timeline
- Start
- 2007-01
- Primary completion
- 2009-05
- Completion
- 2009-06
Publications
- Background Hanania NA, Singh S, El-Wali R, Flashner M, Franklin AE, Garner WJ, Dickey BF, Parra S, Ruoss S, Shardonofsky F, O'Connor BJ, Page C, Bond RA. The safety and effects of the beta-blocker, nadolol, in mild asthma: an open-label pilot study. Pulm Pharmacol Ther. 2008;21(1):134-41. doi: 10.1016/j.pupt.2007.07.002. Epub 2007 Jul 17.
- Background Nguyen LP, Lin R, Parra S, Omoluabi O, Hanania NA, Tuvim MJ, Knoll BJ, Dickey BF, Bond RA. Beta2-adrenoceptor signaling is required for the development of an asthma phenotype in a murine model. Proc Natl Acad Sci U S A. 2009 Feb 17;106(7):2435-40. doi: 10.1073/pnas.0810902106. Epub 2009 Jan 26.
Drugs
| Evaluation | Drug | Modality | Dose | Route |
|---|---|---|---|---|
| Subject | Nadolol | Unknown | 1.25 mg | Oral |
| Subject | Nadolol | Unknown | 2.5 mg | Oral |
| Subject | Nadolol | Unknown | 5 mg | Oral |
| Subject | Nadolol | Unknown | 10 mg | Oral |
| Subject | Nadolol | Unknown | 20 mg | Oral |
| Subject | Nadolol | Unknown | 40 mg | Oral |